FDA 483 OBSERVATION · #124 OF 1,923 MOST-CITED
Lack of or inadequate receiving acceptance procedures
FDA cited this observation 243 times across 230 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The firm has not established, or has inadequately established, procedures for acceptance of incoming product — the controls that verify components, materials, and services meet specified requirements before they are used or otherwise released for production under §820.80(b).
Why FDA writes it — Receiving acceptance is the first defense against nonconforming inputs entering the build. Without it, defective or out-of-spec components propagate into finished devices undetected, and FDA protects against a firm that discovers a bad material only after it has already been assembled into product.
- Establish a receiving-acceptance procedure defining inspection, test, or verification for each material against documented specifications.
- Hold incoming product in a controlled quarantine state until acceptance is completed and recorded.
- Record the acceptance results, the equipment used, and the individual who accepted the material, per §820.80(e).
- Use supplier controls and certificates of analysis as inputs to — not replacements for — a defined acceptance decision.
- The firm leans entirely on supplier COAs and performs no independent receiving verification.
- Specifications for incoming components are absent or vague, so there is nothing to inspect against.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.6× the rate of the average FDA-cited firm (12.6% vs 7.8%), across 230 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for acceptance of incoming product have not been adequately established.
Procedures for acceptance of incoming product have not been adequately established.
Procedures for acceptance of incoming product have not been adequately established.
Procedures for acceptance of incoming product have not been adequately established.
Procedures for acceptance of incoming product have not been adequately established.
Procedures for acceptance of incoming product have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →